Baird Maintains Neutral Rating on Biogen (BIIB), Gilenya Losing Momentum
Tweet Send to a Friend
Baird is maintaining their Neutral rating and $62 price target on shares of Biogen (NASDAQ: BIIB) as new numbers from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
